BRIEF published on 03/11/2026 at 18:35, 8 months 1 day ago Inoviem Scientific Advances Drug Development with Patient-Centric Approach Personalized Medicine Pharmaceutical Innovation Inoviem Scientific Patient-centric Drug Development Preclinical Programs
PRESS RELEASE published on 03/11/2026 at 18:30, 8 months 1 day ago ATON: UPDATE ON THE ACTIVITIES OF ITS SUBSIDIARY INOVIEM SCIENTIFIC Aton Group's subsidiary, Inoviem Scientific, transforms drug development by prioritizing patient samples & AI technology, accelerating preclinical programs with high-value translational data AI Technology Drug Development Inoviem Scientific Aton Group Patient Sample
BRIEF published on 03/11/2026 at 18:20, 8 months 1 day ago Inoviem Scientific: Advances in Pharmaceutical Development Personalized Medicine Pharmaceutical Development Translational Pharmacology Inoviem Scientific Integrated Platform
BRIEF published on 02/18/2026 at 18:35, 8 months 22 days ago Hadrien Lanvin Appointed Deputy CEO of Aton Group Biotechnology Strategic Growth Deputy CEO Hadrien Lanvin Aton Group
BRIEF published on 02/18/2026 at 18:35, 8 months 22 days ago Hadrien Lanvin appointed Deputy Managing Director of the Aton Group Biotechnology Life Sciences Appointment Hadrien Lanvin Aton Group
PRESS RELEASE published on 02/18/2026 at 18:30, 8 months 22 days ago ATON APPOINTS HADRIEN LANVIN AS DEPUTY CEO Aton Group appoints Hadrien Lanvin as Deputy CEO to drive value and visibility, strengthening leadership and strategic positioning. Focus on maximizing asset portfolio valuation and accelerating development Valuation Leadership Deputy CEO Hadrien Lanvin Aton Group
BRIEF published on 10/31/2025 at 18:05, 1 year ago 2025 Half-Year Results: Aton Confirms its Recovery Financial Recovery 2025 Results PIMS Technology Inoviem Scientific B Cell Design
BRIEF published on 10/08/2025 at 18:05, 1 year 1 month ago Strategic partnership between Inoviem Scientific and abc biopply in preclinical oncology Strategic Partnership 3D Models Therapeutic Innovation Preclinical Oncology Translational Pharmacology
BRIEF published on 09/29/2025 at 08:05, 1 year 1 month ago ATON Presents its New Strategy at the European MidCap Event 2025 Investors Governance Financial Strategy Aton European MidCap
BRIEF published on 09/17/2025 at 18:05, 1 year 1 month ago PIMS Technology secures €500,000 in funding from Bpifrance Funding Marketing Precision Medicine Bpifrance PIMS Technology
Published on 11/12/2026 at 19:20, 2 hours 55 minutes ago HELLENiQ ENERGY Holdings S.A Announces 3Q 2026 Financial Results
Published on 11/12/2026 at 15:55, 6 hours 20 minutes ago DIAGENS Leads in Two Major Global AI Benchmarks and Extends Chest and Abdominal CT Analysis to 509 Imaging Targets, Ushering in a New Era for Medical Imaging AI
Published on 11/12/2026 at 14:31, 7 hours 44 minutes ago First Breach Inc. Announces Third Quarter 2026 Earnings Conference Call
Published on 11/12/2026 at 14:00, 8 hours 15 minutes ago GameSquare Announces Peaky Blinders Digital Fan Experience, Advancing the Company's IP Monetization Strategy
Published on 11/12/2026 at 14:00, 8 hours 15 minutes ago NuRAN Wireless Highlights Recurring Revenue Economics and Growth Potential of Its 5,092-Tower Contracted NaaS Portfolio
Published on 11/12/2026 at 19:50, 2 hours 25 minutes ago Eurobattery Minerals receives shareholder requests for additional items on the agenda of the upcoming Extraordinary General Meeting
Published on 11/12/2026 at 18:25, 3 hours 50 minutes ago OMAN AWARDS TWO GREEN HYDROGEN PROJECTS IN DUQM AND LAUNCHES ROUND 4 GREEN-POWERED DATA CENTRE HYDROGEN AUCTION AT COP31
Published on 11/12/2026 at 18:14, 4 hours 1 minute ago EQS-Adhoc: HUGO BOSS AG: Daniel Grieder to step down as CEO of HUGO BOSS effective December 31, 2026 - David Epstein appointed as CEO effective January 1, 2027
Published on 11/12/2026 at 18:00, 4 hours 15 minutes ago Deutsche EuroShop on track – 2026 forecast raised
Published on 11/12/2026 at 17:53, 4 hours 22 minutes ago Brockhaus Technologies AG: 9M 2026 revenue of €20.0 million and adjusted EBITDA of €-1.0 million; revenue and adjusted EBITDA for 2026 expected at the lower end of the forecast
Published on 11/12/2026 at 18:36, 3 hours 39 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/10/2026
Published on 11/12/2026 at 18:00, 4 hours 15 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 12, 2026
Published on 11/12/2026 at 17:40, 4 hours 35 minutes ago Financial information for the period ended 30 September 2026
Published on 11/12/2026 at 08:56, 13 hours 18 minutes ago Number of shares and voting rights - October 2026 (In French only)
Published on 11/12/2026 at 08:40, 13 hours 35 minutes ago FREY forms a €400 million equity partnership with GIC to invest in premium European retail parks
